GlassScriptPhysician profile
Janis J Galm
NPI 1518990589
$306.17
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $46.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $99.73 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $39.60 | 2019 | |
| Pfizer INC. | $26.28 | 2019 | |
| Genentech USA, INC. | $20.99 | 2019 | |
| Dermira, INC. | $18.73 | 2019 | |
| Roche Diagnostics Corporation | $17.94 | 2019 | |
| Shire North American Group INC | $15.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.62 | 2019 | |
| Glaxosmithkline, LLC. | $14.25 | 2019 | |
| Adlon Therapeutics L.P. | $13.91 | 2019 | |
| Kaleo, INC. | $12.68 | 2020 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janis Galm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.